Associated Genetic Biomarkers
NCI Definition: A malignant mesenchymal fibroblastic neoplasm affecting the soft tissue and bone. 
Fibrosarcomas most frequently harbor alterations in CDKN2A, TP53, CDKN2B, EP300, and NOTCH1 .
CDKN2A Loss, CDKN2B Loss, TP53 Mutation, NOTCH1 Mutation, and NOTCH1 Missense are the most common alterations in fibrosarcoma .
There are 3 clinical trials for fibrosarcoma, of which 3 are open and 0 are completed or closed. Of the trials that contain fibrosarcoma as an inclusion criterion, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open).
MYCN is the most frequent gene inclusion criterion for fibrosarcoma clinical trials .
Anti-gd2 hu3f8/anti-cd3 huokt3 bispecific antibody, doxorubicin, and pembrolizumab are the most common interventions in fibrosarcoma clinical trials.
Significant Genes in Fibrosarcoma
MYCN is an inclusion eligibility criterion in 1 clinical trial for fibrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and fibrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.